O-27 - Using high-specific activity Samarium-153 for the development of [153Sm] Sm DOTA-TATE for targeted radionuclide therapy of neuroendocrine tumors

Koen Vermeulen, Michiel Van de Voorde, Noami Daems, Charlotte Duchemin, Sunay Rodriguez Pérez, Melissa Crabbé, Heinke Reinhard, Bernard Ponsard, Lorain Geenen, Julie Nonnekens, Laura Lambert, Cyril Bernerd, Andrew Burgoyne, Thomas Elias Cocolios, Thierry Stora, Maarten Ooms

    Research outputpeer-review


    Samarium-153 is a promising radionuclide for targeted radionuclide therapy (TRNT) because of its highly favorable decay characteristics. 153Sm has a half-life of 1.93 days and emits Beta- particles (705 keV, 635 keV) which are suitable for therapy. 153Sm also emits Y photons (103 keV) with characteristics that allow SPECT imaging, making 153Sm a high-potential theranostic radioisotope.
    The full potential of 153Sm is currently not being exploited because of the limited specific activity available as a result of its carrier-added production route (152Sm(n,Y)153Sm). In our previous work, we tried to remedy this by applying mass separation after the neutron activation to produce 153Sm with a much higher specific activity [1]. In this study, we use high specific activity (HSA) samarium-153 for the radiolabeling of the somatostatin analogue DOTA-TATE. This study
    reports the radiolabeling and early biological evaluation of [153Sm] Sm-DOTA-TATE.
    Original languageEnglish
    Pages (from-to)S20
    Number of pages1
    JournalNuclear Medicine and Biology
    Issue numberSupplement
    StatePublished - May 2022

    Cite this